NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies

This study is NOT currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

15-AR-0185

Sponsoring Institute

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Recruitment Detail

Type: Completed Study; data analyses ongoing
Gender: Male & Female
Min Age: 18
Max Age: 100

Referral Letter Required

No

Population Exclusion(s)

Children

Special Instructions

Currently Not Provided

Keywords

Anti-DNA Antibody;
Xeljanz;
JAK-IN-LUPUS;
Tolerability;
Jak

Recruitment Keyword(s)

None

Condition(s)

Systemic Lupus Erythematosus

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

Drug: Tofacitinib
Drug: Placebo

Supporting Site

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Background:

Systemic lupus erythematosus (lupus) is an autoimmune disease that often involves many systems and organs of the body. Symptoms can include fever, joint pains, and rashes. Serious lupus can also damage organs like the kidneys, lungs, or brain. Drugs used for lupus can have serious side effects. Also, the drugs don t help some people. Researchers want to find new, more effective and safe treatments.

Objective:

To evaluate the safety and tolerability of the drug tofacitinib (study drug) in people with lupus.

Eligibility:

People ages 18 and older who have mild to moderate lupus and are not currently or haven t recently had certain lupus treatments.

Design:

Participants will be screened in another protocol.

Participants will have 7 five-hour visits over about 3 months. They will fill out multiple questionnaires. They will have tests, including:

-Physical exam

-Blood and urine tests

-ECG/EKG: Soft electrodes are stuck to the skin to monitor the heart.

-Optional SphygmoCor: Cuffs are attached to the arm and thigh to measure blood pressure and flow speed.

-Optional Endopat: A thimble-shaped cup is placed on the finger to measure blood flow. A cuff is put on the arm to measure blood pressure and flow.

-Optional CAVI: ECG electrodes are placed on both wrists, a microphone placed on the chest, and a blood pressure cuff placed on each arm and leg to measure blood pressure and velocity.

Participants will receive either the study drug or a placebo. They will take this twice a day by mouth for 56 days.

Participants will be contacted by phone 4 times.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

-Subject is capable of providing written informed consent.

-Subject is greater than or equal to 18 years old.

-Meets at least 4 of 11 modified American College of Rheumatology (ACR) (1997) Revised Criteria for the Classification of Systemic Lupus Erythematosus.

-Has mild to moderate disease activity defined as a SLEDAI 2K more than or equal to 2 and less than or equal to 14 at the screening visit.

-If on glucocorticoids, the dose must be less than or equal to 20 mg daily and stable for the 4 weeks prior to screening visit.

-If on hydroxychloroquine or other antimalarials such as chloroquine or quinacrine, the dose must have been stable for the 12 weeks prior to screening visit. The maximum allowed dose is hydroxychloroquine up to 400 mg/day or 6.5 mg/kg/day if more than 400 mg/day. The maximum allowed dose for chloroquine phosphate is up to 500 mg daily and for quinacrine up to100 mg daily.

-Males and females with potential for reproduction must agree to practice effective birth control measures. Females should be on adequate contraception if they are of child-bearing potential documented by a clinician, unless patients or spouse have previously undergone a sterilization procedure. Adequate will be considered intrauterine device (IUD) alone or hormone implants, hormone patches, injectables, or oral contraceptives plus a barrier method (male condom, female condom or diaphragm), abstinence or a vasectomized partner

-If patients are on ACE inhibitors or ARB medications, dose of this medication must be stable for 4 weeks prior to study entry.

-Patients may be on lipid lowering medications if initiated at least 6 months prior to the screening visit.

EXCLUSION CRITERIA:

-Pregnant or lactating women. Women of childbearing potential are required to have a negative pregnancy test at screening.

-Current or prior treatment with rituximab, belimumab or any other biologic agent in the 6 months prior to screening.

-Current treatment with immunosuppressive drugs (methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus). Glucocorticoids are allowed as per the inclusion criteria. At the investigator s discretion, glucocorticoids may be tapered during the study.

-Patients previously on methotrexate, mycophenolate mofetil, cyclosporine or tacrolimus should have stopped it for at least 8 weeks at the time of screening.

-Treatment with cyclophosphamide, pulse methylprednisolone or IVIG within the 6 months prior to screening.

-Increase in glucocorticoid dose within 4 weeks of screening.

-A history of drug or alcohol abuse within the 6 months prior to screening.

-History of chronic liver disease or elevated LFTs:

--ALT or AST greater than or equal to 2x upper limit of normal at screening

--serum unconjugated bilirubin > 2mg/dL at screening

-Dialysis or serum creatinine >1.5mg/dL.

-Protein to creatinine ratio of more than 1 mg/mg or 24 hours urine protein of more than 1000 mg.

-Active urinary sediment (WBC, RBC or mixed cellular casts 1+ or more /hpf).

-Hypercholesterolemia: Values after an 8-12 hour fasting blood specimen: total cholesterol >250 mg/dL or LDL >180 mg/dl or hypertriglyceridemia (triglyceride >300 mg/dL) within plus or minus 45 days of screening visit.

-Active infection that requires the use of oral or intravenous antibiotics and has not resolved at least 2 weeks prior to the administration of the first dose of study medication.

-Active chronic infections including but not limited to HIV, Hepatitis B, Hepatitis C, and BK viremia at screening visit.

-History of cancer.

-Known active tuberculosis or untreated latent tuberculosis.

-History of opportunistic infections.

-Subjects with active renal or central nervous system disease or a BILAG A in any organ system.

-WBC <2500/Microlitre or ANC <1,000/Microlitre, Hgb <9.0 g/dL or platelets <70,000/Microlitre or absolute lymphocyte count < 500/Microlitre.

-Current treatment with potent inhibitors of Cytochrome P450 3A4 (CYP3A4) (e.g., ketoconazole) or receiving one or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole) that would increase serum availability of tofacitinib. Past treatment with the above mentioned agent is allowed if it was more than a week prior to the administration of the first dose of study medication.

-Significant impairment of major organ function (lung, heart, liver, kidney) or any condition that, in the opinion of the Investigator, would jeopardize the subject s safety following exposure to the study drug.


--Back to Top--

Citations:

O'Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013 Jan 10;368(2):161-70. doi: 10.1056/NEJMra1202117.

O'Shea JJ, Laurence A, McInnes IB. Back to the future: oral targeted therapy for RA and other autoimmune diseases. Nat Rev Rheumatol. 2013 Mar;9(3):173-82. doi: 10.1038/nrrheum.2013.7. Epub 2013 Feb 19.

Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Sarfaraz A. Hasni, M.D.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)



Yenealem Temesgen-Oyelakin, R.N.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institutes of Health
Building 10
Room 6N216
10 Center Drive
Bethesda, Maryland 20892
(301) 451-4990
yenealem.temesgen-oyelakin@nih.gov

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: 1-866-411-1010
PRPL@cc.nih.gov

Clinical Trials Number:

NCT02535689

--Back to Top--